Related Experiment Video
Updated: Jul 13, 2025

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
Published on: February 5, 2020
Characterization of Immunosuppressive Myeloid Cells in Merkel Cell Carcinoma: Correlation with Resistance to PD-1
Shira Tabachnick-Cherny1, Thomas Pulliam1, Haroldo J Rodriguez1
1Department of Dermatology, University of Washington, Seattle, Washington.
Purpose:
Merkel cell carcinoma (MCC) is a highly immunogenic skin cancer. Although essentially all MCCs are antigenic through viral antigens or high tumor mutation burden, MCC has a response rate of only approximately 50% to PD-(L)1 blockade suggesting barriers to T-cell responses. Prior studies of MCC immunobiology have focused on CD8 T-cell infiltration and their exhaustion status, while the role of innate immunity, particularly myeloid cells, in MCC remains underexplored.
Experimental Design:
We utilized single-cell transcriptomics from 9 patients with MCC and multiplex IHC staining of 54 patients' preimmunotherapy tumors, to identify myeloid cells and evaluate association with immunotherapy response.
Results:
Single-cell transcriptomics identified tumor-associated macrophages (TAM) as the dominant myeloid component within MCC tumors. These TAMs express an immunosuppressive gene signature characteristic of monocytic myeloid-derived suppressor cells and importantly express several targetable immune checkpoint molecules, including PD-L1 and LILRB receptors, that are not present on tumor cells. Analysis of 54 preimmunotherapy tumor samples showed that a subset of TAMs (CD163+, CD14+, S100A8+) selectively infiltrated tumors that had significant CD8 T cells. Indeed, higher TAM prevalence was associated with resistance to PD-1 blockade. While spatial interactions between TAMs and CD8 T cells were not associated with response, myeloid transcriptomic data showed evidence for cytokine signaling and expression of LILRB receptors, suggesting potential immunosuppressive mechanisms.
Conclusions:
This study further characterizes TAMs in MCC tumors and provides insights into their possible immunosuppressive mechanism. TAMs may reduce the likelihood of treatment response in MCC by counteracting the benefit of CD8 T-cell infiltration. See related commentary by Silk and Davar, p. 1076.
Insights
Tumor-associated macrophages (TAMs) in Merkel cell carcinoma (MCC) may hinder immunotherapy response by suppressing T-cell activity. Targeting these TAMs could improve treatment outcomes for this skin cancer.
Area of Science:
- Immunology
- Oncology
- Dermatology
Background:
- Merkel cell carcinoma (MCC) is an aggressive skin cancer with variable response to PD-(L)1 blockade.
- Prior research on MCC immunobiology has focused on T-cells, leaving the role of innate immunity, particularly myeloid cells, underexplored.
Purpose of the Study:
- To identify myeloid cell populations in MCC tumors.
- To evaluate the association of myeloid cells with response to immunotherapy.
- To elucidate potential immunosuppressive mechanisms employed by myeloid cells in MCC.
Main Methods:
- Single-cell transcriptomics was performed on MCC tumors from 9 patients.
- Multiplex immunohistochemistry (IHC) staining was conducted on 54 pre-immunotherapy MCC tumors.
- Analysis focused on identifying myeloid cell subsets and their correlation with clinical outcomes.
Main Results:
- Tumor-associated macrophages (TAMs) were identified as the dominant myeloid component in MCC, expressing immunosuppressive markers and immune checkpoint molecules (PD-L1, LILRB).
- Higher TAM prevalence correlated with resistance to PD-1 blockade, particularly in tumors with significant CD8 T-cell infiltration.
- TAMs exhibited cytokine signaling, suggesting potential immunosuppressive mechanisms that counteract T-cell responses.
Conclusions:
- TAMs represent a key myeloid component in MCC tumors with a distinct immunosuppressive phenotype.
- TAMs may reduce the efficacy of immunotherapy in MCC by inhibiting CD8 T-cell anti-tumor activity.
- Targeting TAMs presents a potential strategy to overcome immunotherapy resistance in Merkel cell carcinoma.
More Related Videos
08:30Immunophenotyping of Orthotopic Homograft Syngeneic of Murine Primary KPC Pancreatic Ductal Adenocarcinoma by Flow Cytometry
Published on: October 9, 2018
09:32Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
Published on: February 8, 2018
Related Concept Videos
Abnormal Proliferation
Mitogens and the Cell Cycle